1527 studies found for:    melanoma
Show Display Options
Rank Status Study
21 Completed
Has Results
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Condition: Melanoma
Interventions: Drug: Glycoprotein 100 (GP100): 209-217 (210M);   Drug: Interleukin-2 (IL-2);   Drug: Montanide ISA 51;   Drug: Melanoma antigen recognized by T-cells (MART)-1: 27-35;   Drug: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1;   Drug: melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
22 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
23 Recruiting Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
Condition: Melanoma
Intervention: Other: biological collection
24 Completed Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
Conditions: Stage IV Melanoma;   Recurrent Melanoma
Intervention: Biological: recombinant interferon beta
25 Active, not recruiting M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Condition: Melanoma
Intervention: Biological: M-Vax- autologous, hapten-modified melanoma vaccine
26 Unknown  A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Condition: Melanoma
Interventions: Biological: HyperAcute vaccine;   Drug: Pegylated Interferon-Alpha 2b
27 Completed Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100 antigen;   Biological: tyrosinase peptide;   Biological: recombinant MAGE-3.1 antigen;   Biological: multi-epitope melanoma peptide vaccine;   Biological: incomplete Freund's adjuvant;   Drug: Montanide ISA 51 VG;   Drug: agatolimod sodium;   Other: laboratory biomarker analysis
28 Recruiting Adoptive T Cell Therapy for Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Tumor Infiltrating Lymphocytes
29 Active, not recruiting A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma
Conditions: Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma
Intervention: Biological: CB-10-01 (Transgenic Lymphocyte Immunization)
30 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim
31 Completed Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
Condition: Melanoma
Interventions: Biological: Autologous, DNP-modified vaccine (M-Vax);   Biological: Autologous, DNP-Modified Melanoma Vaccine;   Biological: Autologous, DNP-Modified Vaccine
32 Recruiting Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Condition: Melanoma
Intervention: Other: Sampling of blood
33 Active, not recruiting Pilot Study of Infrared Imaging of Cutaneous Melanoma
Condition: Melanoma
Intervention:
34 Active, not recruiting THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease
Condition: Ocular Melanoma
Intervention: Drug: Ipilimumab
35 Completed Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma
Condition: Melanoma
Interventions: Genetic: Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes;   Biological: Intranodal booster immunizations with synthetic melanoma associated epitopes
36 Unknown  Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine;   Biological: tyrosinase peptide
37 Completed Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Conditions: Metastatic Melanoma;   Absence of CNS Metastases
Intervention: Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
38 Terminated
Has Results
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Conditions: Metastatic Melanoma;   Metastatic Renal Cancer
Interventions: Drug: Zanolimumab;   Drug: Aldesleukin
39 Completed
Has Results
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
Condition: Melanoma and Brain Metastases
Intervention: Drug: GSK2118436
40 Suspended Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Condition: Melanoma
Interventions: Biological: MELITAC 12.1;   Drug: Imiquimod

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years